Back to News
Market Impact: 0.2
PolyPid Ltd. Introduces PD01B and Outlines D-PLEX₁₀₀ Milestones
Source: Nasdaq
Healthcare & BiotechProduct LaunchesTechnology & Innovation
PolyPid unveiled an expanded pipeline strategy and introduced PD01B, a product candidate for hyper-localized, controlled-release antibiotic treatment of diabetic foot infections. The candidate uses the company’s Kynatrix technology and combines doxycycline with an ingredient not specified in the provided text; no clinical or commercial results were reported.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.15
Ticker Sentiment
PYPD0.45
More News
- What investors need to know about Alphabet's stock-busting earnings report
- Microsoft's Big Bets on AI Start to Pay Off
- Microsoft’s strong quarter backs up its stock rebound. Here's our new price target
- Google struggling to make AI Mode searches pay
- As Waymo expands overseas, it remains a niche cash-burning business
- Hexaware Q3 2026 slides show AI push as revenue growth moderates